It is used in the treatment of acute hepatic porphyria (AHP) and acts by degrading 5-aminolevulinic acid synthase 1 (ALAS1) mRNA, resulting in reduced levels of intermediates associated with AHP attacks. This evidence concerns the gene ALAS1 and anhaptoglobinemia.